In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem
复制标题
新型碳青霉烯类 RS-533 的体外抗需氧和厌氧革兰氏阳性和革兰氏阴性细菌活性以及 β-内酰胺酶稳定性
DOI：
10.1128/aac.30.6.828
复制
发表时间：
1986
影响因子：
4.9
通讯作者：
P. Labthavikul
中科院分区：
文献类型：
--
作者：
H. Neu;N. Chin;G. Saha;P. Labthavikul
RS-533是一种新型碳青霉烯类抗生素。其活性与亚胺培南和新型头孢菌素、氨曲南、哌拉西林和妥布霉素进行了比较。 RS-533 的活性与亚胺培南相当，在浓度小于或等于 2 微克/毫升时抑制大多数肠杆菌科、链球菌、葡萄球菌和拟杆菌属。 RS-533 可抑制对头孢他啶、氨曲南和头孢哌酮耐药的阴沟肠杆菌、弗氏柠檬酸杆菌和粘质沙雷菌，但 RS-533 不能抑制所有耐甲氧西林金黄色葡萄球菌或嗜麦芽假单胞菌。它抑制肠杆菌科和铜绿假单胞菌的妥布霉素耐药成员。 RS-533 可稳定抵抗常见染色体和质粒介导的 β-内酰胺酶的攻击，并且是许多 β-内酰胺酶的有效抑制剂。
RS-533 is a novel carbapenem antibiotic. Its activity was compared with that of imipenem and the new cephalosporins, aztreonam, piperacillin, and tobramycin. RS-533 had activity comparable to that of imipenem, inhibiting the majority of the Enterobacteriaceae, streptococci, staphylococci, and Bacteroides species at concentrations of less than or equal to 2 micrograms/ml. RS-533 inhibited Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens resistant to ceftazidime, aztreonam, and cefoperazone, but RS-533 did not inhibit all methicillin-resistant Staphylococcus aureus or Pseudomonas maltophilia. It inhibited tobramycin-resistant members of the Enterobacteriaceae and Pseudomonas aeruginosa. RS-533 was stable against attack by common chromosomal and plasmid-mediated beta-lactamases and was an effective inhibitor of many beta-lactamases.